dc.contributor.author | Mohammadi, M | |
dc.contributor.author | IJzerman, NS | |
dc.contributor.author | Hohenberger, P | |
dc.contributor.author | Rutkowski, P | |
dc.contributor.author | Jones, RL | |
dc.contributor.author | Martin-Broto, J | |
dc.contributor.author | Gronchi, A | |
dc.contributor.author | Schöffski, P | |
dc.contributor.author | Vassos, N | |
dc.contributor.author | Farag, S | |
dc.contributor.author | Baia, M | |
dc.contributor.author | Oosten, AW | |
dc.contributor.author | Steeghs, N | |
dc.contributor.author | Desar, IME | |
dc.contributor.author | Reyners, AKL | |
dc.contributor.author | van Sandick, JW | |
dc.contributor.author | Bastiaannet, E | |
dc.contributor.author | Gelderblom, H | |
dc.contributor.author | Schrage, Y | |
dc.date.accessioned | 2021-06-11T13:29:23Z | |
dc.date.available | 2021-06-11T13:29:23Z | |
dc.date.issued | 2021-03-31 | |
dc.identifier.citation | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021 | |
dc.identifier.issn | 0748-7983 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4638 | |
dc.identifier.eissn | 1532-2157 | |
dc.identifier.doi | 10.1016/j.ejso.2021.03.234 | |
dc.description.abstract | Background Oesophageal gastrointestinal stromal tumours (GISTs) account for ≤1% of all GISTs. Consequently, evidence to guide clinical decision-making is limited.Methods Clinicopathological features and outcomes in patients with primary oesophageal GIST from seven European countries were collected retrospectively.Results Eighty-three patients were identified, and median follow up was 55.0 months. At diagnosis, 59.0% had localized disease, 25.3% locally advanced and 13.3% synchronous metastasis. A biopsy (Fine Needle aspiration n = 29, histological biopsy n = 31) was performed in 60 (72.3%) patients. The mitotic count was low (<5 mitoses/50 High Power Fields (HPF)) in 24 patients and high (≥5 mitoses/50 HPF) in 27 patients. Fifty-one (61.4%) patients underwent surgical or endoscopic resection. The most common reasons to not perform an immediate resection (n = 31) were; unresectable or metastasized GIST, performance status/comorbidity, patient refusal or ongoing neo-adjuvant therapy. The type of resections were enucleation (n = 11), segmental resection (n = 6) and oesophagectomy with gastric conduit reconstruction (n = 33), with median tumour size of 3.3 cm, 4.5 cm and 7.7 cm, respectively. In patients treated with enucleation 18.2% developed recurrent disease. The recurrence rate in patients treated with segmental resection was 16.7% and in patients undergoing oesophagectomy with gastric conduit reconstruction 36.4%. Larger tumours (≥4.0 cm) and high (>5/5hpf) mitotic count were associated with worse disease free survival.Conclusion Based on the current study, enucleation can be recommended for oesophageal GIST smaller than 4 cm, while oesophagectomy should be preserved for larger tumours. Patients with larger tumours (>4 cm) and/or high mitotic count should be treated with adjuvant therapy. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-03-09 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1016/j.ejso.2021.03.234 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2021-03-31 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.embargo.terms | Not known | |
icr.researchteam | Sarcoma Clinical Trials (R Jones) | |
icr.researchteam | Sarcoma Clinical Trials (R Jones) | en_US |
dc.contributor.icrauthor | Jones, Robin | |